SEARCH

SEARCH BY CITATION

References

  • 1
    Anonymous. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997; 26(Suppl):2S10S. MEDLINE
  • 2
    Mondelli MU. Is there a role for immune responses in the pathogenesis of hepatitis C? J Hepatol 1996; 25:232238. MEDLINE
  • 3
    Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ, Choo Q-L, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104:580587. MEDLINE
  • 4
    Koziel MJ, Dudley D, Wong JT, Dienstag JL, Houghton M, Ralston R, Walker BD. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149:33393344. MEDLINE
  • 5
    Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T, Schianchi C, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19:286295. MEDLINE
  • 6
    Wong DK, Dudley DD, Afdhal NH, Dienstag JL, Rice CM, Wang L, Houghton M, et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998; 160:14791488. MEDLINE
  • 7
    Zibert A, Kraas W, Meisel H, Jung G, Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol 1997; 71:41234127. MEDLINE
  • 8
    Scarselli E, Cerino A, Esposito G, Silini E, Mondelli MU, Traboni C. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (E2; gp70) hypervariable region 1 in hepatitis C viremic patients. J Virol 1995; 69:44074412. MEDLINE
  • 9
    Cerino A, Bissolati M, Cividini A, Nicosia A, Esumi M, Hayashi N, Mizuno K, et al. Antibody responses to the hepatitis C virus (HCV) E2 protein: relationship to viraemia and prevalence in anti-HCV seronegative subjects. J Med Virol 1997; 51:15. MEDLINE
  • 10
    da Silva-Cardoso M, Siemoneit K, Nemecek V, Epple S, Koerner K, Kubanek B. The serology of hepatitis C virus infection: antibody crossreaction in the hypervariable region 1. Arch Virol 1995; 140:17051713. MEDLINE
  • 11
    Jackson P, Petrik J, Alexander GJM, Pearson G, Allain J-P. Reactivity of synthetic peptides representing selected sections of hepatitis c virus core and envelope proteins with a panel of hepatitis C virus-seropositive human plasma. J Med Virol 1997; 51:6779. MEDLINE
  • 12
    Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180:842848. MEDLINE
  • 13
    Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infection. Proc Natl Acad Sci U S A 1992; 89:34683472. MEDLINE
  • 14
    Taniguchi S, Okamoto H, Sakamoto M, Kojima M, Tsuda F, Tanaka T, Munekata E, et al. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology 1993; 195:297301. MEDLINE
  • 15
    Lechner S, Rispeter K, Meisel H, Kraas W, Jung G, Roggendorf M, Zibert A. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology 1998; 243:313321. MEDLINE
  • 16
    Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, et al. A quantitative test to estimate neutralizing antibodies to hepatitis C virus: cytofluorometric assessment of envelope glycoprotein E2 binding to target cells. Proc Natl Acad Sci U S A 1996; 93:(5) 17591763.
  • 17
    Pileri P, Yasushi U, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938941. MEDLINE
  • 18
    Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 1997; 25:12451249. MEDLINE
  • 19
    Zibert A, Schreier E, Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 1995; 208:653661. MEDLINE
  • 20
    Hattori M, Yoshioka K, Aiyama T, Iwata K, Terazawa Y, Ishigami M, Yano M, et al. Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: relation to viral loads and response to interferon. Hepatology 1998; 27:17031710. MEDLINE
  • 21
    Yoshioka K, Aiyama T, Okumura A, Takayanagi M, Iwata K, Ishikawa T, Nagai Y, et al. Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a. J Infec Dis 1997; 175:505510.
  • 22
    Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, Yoshikura H. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996; 223:409412. MEDLINE
  • 23
    Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci 1996; 93:1539415399. MEDLINE
  • 24
    Lesniewski RR, Boardway KM, Casey JM, Desai SM, Devare SG, Leung TK, Mushawar IK. Hypervariable 5′-terminus of hepatitis C virus E2/NS1 encodes antigenically distinct variants. J Med Virol 1993; 40:150156. MEDLINE
  • 25
    Kumar U, Monjardino J, Thomas HC. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. 4 Gastroenterology 1994; 106:10721075. MEDLINE
  • 26
    Booth JCL, Kumar U, Webster D, Monjardino J, Thomas HC. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 1998; 27:223227. MEDLINE
  • 27
    van Doorn L-J, Capriles I, Maertens G, DeLeys R, Murray K, Kos T, Schellekens H, et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol 1995; 69:773778. MEDLINE
  • 28
    Chesebro B, Wehrly K, Nishio J, Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 1992; 66:65476554. MEDLINE
  • 29
    Fouchier RAM, Groenink M, Kootstra A, Tersmette M, Huisman HG, Miedema F, Schitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66:31833187. MEDLINE
  • 30
    Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant for cell tropism in HIV-1. Science 1991; 253:7174. MEDLINE
  • 31
    Brambilla S, Bellati G, Asti M, Lisa A, Candusso ME, D'Amico M, Grassi G, et al. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. Hepatology 1998; 27:16781686. MEDLINE
  • 32
    Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21:285290. MEDLINE
  • 33
    Pessi A, Bianchi E, Bonelli F, Chiappinelli L. Application of the continuous-flow polyamide method to the solid-phase synthesis of a multiple antigen peptide (MAP) based on the sequence of a malaria epitope. J Chem Soc Chem Commun 1990; 1:8.
  • 34
    Cerino A, Mondelli MU. Identification of an immunodominant B-cell epitope on the hepatitis C virus non structural region defined by human monoclonal antibodies. J Immunol 1991; 147:26922696. MEDLINE
  • 35
    Yamaguchi K, Tanaka E, Higashi K, Kiyosawa K, Matsumoto A, Furuta S, Hasegawa A, et al. Adaptation of hepatitis C virus for persistent infection in patients with acute hepatitis. Gastroenterology 1994; 106:13441348. MEDLINE
  • 36
    Puntoriero G, Meola A, Lahm A, Zucchelli S, Bruniercole B, Tafi R, Pezzanera M, et al. Toward a solution for HCV hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J 1998; 17:35213533. MEDLINE
  • 37
    Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, Shimotohno K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 1993; 67:39233930. MEDLINE
  • 38
    Sekiya H, Kato N, Ootsuyama Y, Nakazawa T, Yamauchi K, Shimotohno K. Genetic alterations of the putative envelope proteins encoding region of hepatitis C virus in the progression to relapsed phase from acute hepatitis:humoral immune response to hypervariable region 1. Int J Cancer 1994; 57:664670. MEDLINE
  • 39
    Chen M, Sällberg M, Sönnerborg A, Jin L, Birkett A, Peterson D, Weiland O, et al. Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein. Hepatology 1998; 28:219224. MEDLINE
  • 40
    Mondelli MU, Zorzoli I, Cerino A, Cividini A, Bissolati M, Perfetti V, Anesi E, et al. Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications. J Hepatol 1998; 29:879886. MEDLINE
  • 41
    Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787793. MEDLINE
  • 42
    Manzin A, Solforosi L, Petrelli E, Macarri G, Tosone G, Piazza M, Clementi M. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol 1998; 72:62716276. MEDLINE
  • 43
    McAllister J, Casino C, Davidson F, Power J, Lawlor E, Yap P-L, Simmonds P, et al. Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J Virol 1998; 72:48934905. MEDLINE
  • 44
    Lukashov VV, Goudsmit J. Evolution of the human immunodeficiency virus type 1 subtype-specific V3 domain is confined to a sequence space with fixed distance to the subtype consensus. J Virol 1997; 71:63326338. MEDLINE
  • 45
    Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26:13931398. MEDLINE
  • 46
    Lukashov VV, Kuiken CL, Goudsmit J. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol 1995; 69:69116916. MEDLINE
  • 47
    Wolinsky SM, Korber BTM, Neumann AU, Daniels M, Kuntsmann KJ, Whetsell AJ, Furtado MR, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996; 272:537542. MEDLINE
  • 48
    Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, Korber B, Millins JL. Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 1997; 71:74987508. MEDLINE
  • 49
    Bjøro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331:(24) 16071611.
  • 50
    Missale G, Cariani E, Lamonaca V, Ravaggi A, Rossini A, Bertoni R, Houghton M, et al. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 1997; 26:792797. MEDLINE